Tradestie Institutional Equity Comparison Engine

CGEN vs CERS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGEN Overall Edge

CGEN Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin, Momentum & Technical while CERS counters with relative strength in Options & Structure. Fundamentally, CGEN trades at 12.4x Forward P/E with 41.3% operating margin (+102.1% YoY revenue) versus CERS at 126.7x Forward P/E and -1.1% operating margin (+9.5% YoY). In options structure, CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro) against CERS sits in BREAKDOWN (20th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CGEN
CGEN 12.4x vs CERS 126.7x Fwd P/E
Growth & Margin Winner CGEN
Op Margin 41.3% vs -1.1% ยท YoY +102.1% vs +9.5%
Momentum & Technical Winner CGEN
1Y +23.2% vs +17.3% ยท 52W Pos 33% vs 22%
Options & Structure Winner CERS
BREAKDOWN (57th %ile IV) vs BREAKDOWN (20th %ile IV)
CGEN NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
1M Return +2.54%
1Y Return +23.17%
Forward P/E 12.4x
Unified AI Score
47.1 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 54.0 Mom 64.0
CERS NASDAQ
Cerus Corp
Surgical & Medical Instruments & Apparatus
$1.90
+2.15% 1D
Market Cap $375.6M
1M Return -14.41%
1Y Return +17.28%
Forward P/E 126.7x
Unified AI Score
54.4 / 100 HOLD
Tech 65.0 Fund 60.0 Flow 56.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CGEN +23.17% CERS +17.28% Spread: +5.89 pp (CGEN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CGEN Revenue CERS Revenue CGEN Op. Margin CERS Op. Margin Margin Edge
FY2018 $20M $80M -130.5% -72.3% CERS
FY2019 N/A $90M N/A -70.6% CERS
FY2020 $0M $110M -1574.8% -51.1% CERS
FY2021 $10M $160M -584.6% -30.7% CERS
FY2022 $10M $190M -471.7% -18.1% CERS
FY2023 $30M $190M -38.8% -16.1% CERS
FY2024 $30M $200M -53.4% -7.1% CERS
FY2025 $70M $230M 43.1% -3.7% CGEN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CGEN (8) vs CERS (2)
Institutional Metric CGEN CERS Criterion Row Winner
Market Capitalization Scale $193.2M $375.6M Larger Scale CERS
Trailing P/E Ratio Valuation 5.2x N/M Lower Multiple CGEN
Forward P/E Ratio Valuation 12.4x 126.7x Lower Multiple CGEN
Revenue Growth (YoY) Growth +102.1% +9.5% Higher Growth CGEN
Operating Margin (TTM) Profitability 41.3% -1.1% Higher Margin CGEN
Net Profit Margin Profitability 47.9% -3.2% Higher Margin CGEN
Return on Equity (ROE) Capital Efficiency 57.2% -10.7% Higher ROE CGEN
52-Week Range Position Momentum 33% ($1โ€“$3) 22% ($1โ€“$3) Stronger Trend CGEN
Beta / 30D Volatility Risk Regime 1.44ฮฒ ยท 62% Vol 1.62ฮฒ ยท 78% Vol Lower Realized Risk CGEN
Unified Institutional Score Composite Signal 47.1 / 100 (HOLD) 54.4 / 100 (HOLD) Higher Composite CERS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CGEN vs CERS Buy Guide
CGEN BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 57th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CERS BREAKDOWN
119d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 20th %ile
IV Regime Compressed (<25th %ile)
Live CERS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CGEN nor CERS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.